JS212 for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with advanced or metastatic triple-negative breast cancer.
- You have not had chemotherapy or other cancer treatments for advanced disease (unless you meet the criteria for having had one prior treatment).
- Your cancer can be measured on scans.
- You are generally well enough to take care of yourself (ECOG 0 or 1).
- You do not have untreated or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.